Blocknomi
Key Takeaways BioMarin and Ascendis Pharma finalized a comprehensive settlement ending worldwide patent litigation concerning Ascendis’s Yuviwel drug. BioMarin will receive 20% royalties on Yuviwel’s U.S. net revenues and 18%…
Related articles
-
Fake Claude desktop app spreads crypto-stealing malware
Cointelegraph Published 01.09.2026 13:58
-
XRP Hot Streak Cools as Traders Hit a Wall: Where Does It Go Next?
Decrypt Published 25.08.2026 21:46
-
Hugging Face Explores $13 Billion Sale a Month After a Rogue OpenAI Agent Hacked It
Decrypt Published 24.08.2026 22:16
-
Why Bitcoin’s $80,000 rally just flipped from short squeeze to long squeeze
CryptoSlate Published 26.08.2026 11:20
-
Tennessee’s Kalshi Fight Highlights Major Potential Turning Point for Prediction Markets
Bitcoin.com Published 27.08.2026 08:05
-
Zano Activates Hard Fork 6, Opening The Privacy Chain to Exchanges, Bridges and DEXs
Bitcoin.com Published 31.08.2026 19:43
-
BYDFi Joins Coinfest Asia 2026, Connecting With Institutions, Builders and Traders in Bali
Bitcoin.com Published 21.08.2026 10:00
-
10 Best Meme Coins to Watch in 2026 – Is Apeing the Next Breakout With 10,000% ROI Potential?
Blocknomi Published 22.08.2026 05:15